COVID-19

June 30, 2025

Coronavirus pioneer Mark Denison bids farewell to VUMC colleagues after remarkable career

The discoveries about coronavirus biology that Denison and his colleagues made were foundational for the rapid validation of antiviral drugs and development of new vaccines that helped bring the COVID-19 pandemic under control.

By Bill Snyder
December 17, 2024

Immune-suppressing drug does not improve COVID-19 recovery: study

Previous studies suggested that fostamatinib may suppress inflammatory responses triggered by COVID-19 and mitigate ongoing lung injury, decreasing mortality and oxygen requirements.

By Bill Snyder
October 25, 2024

Asthma drug does not speed COVID-19 recovery: study

The study, a randomized and controlled clinical trial, tested the effectiveness of montelukast in 1,250 outpatients with acute post-COVID-19 symptoms.

By Bill Snyder and Shantell Kirkendoll
(iStock)
September 13, 2024

VUMC joins national effort to prevent another pandemic

Developed in the wake of the COVID-19 pandemic, ReVAMPP will support a coordinating center and seven research centers, including VUMC, with a focus on nine virus groups that pose the greatest risk to human health.

By Bill Snyder
May 8, 2024

Supercomputing redesign of a COVID monoclonal antibody

The approach, which combines high-performance computing, simulation, machine learning and experimental validation, will help keep antibody drugs up to date in the future against highly variable viruses.

By Leigh MacMillan
May 7, 2024

A team approach to care 

LSU baseball fan sporting a new set of lungs after VUMC transplant

By Matt Batcheldor
March 5, 2024

CDC encourages additional COVID-19 vaccine dose for patients 65 and older

March 5, 2024

CDC changes community COVID-19 isolation guidance; does not change guidance for Vanderbilt Health employees, patients or facilities

February 22, 2024

NIH-funded trial to determine if immunomodulation can improve brain and cardiovascular dysfunction in Long COVID

Vanderbilt University Medical Center is working with scientists around the U.S. to launch the first Phase III, multicenter, placebo-controlled trial to determine the effect of immunomodulation on Long COVID.
By Nancy Humphrey
January 2, 2024

Team uses COVID-19 to test automated acute disease profiling

An automated solution for creating phenotyping algorithms, PheNorm, worked well to identify symptomatic COVID-19 cases in electronic health records, suggesting that automation could speed high-throughput phenotyping of acute disease.
By Paul Govern
November 6, 2023

Children’s antibodies highly potent against COVID-19: study

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.
By Bill Snyder
September 19, 2023

Updated COVID-19 vaccine available for VUMC employees and patients

The Food and Drug Administration (FDA) recently approved an updated mRNA COVID-19 vaccine. The vaccine provides better protection against current strains of COVID-19 that are circulating as we transition into the fall/winter virus season.
By VUMC News and Communications
September 13, 2023

James Crowe’s antibody research lands American Society for Microbiology Award

Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.
By Bill Snyder
1 2 3 … 38